Search for a trial | Research with human participants

2 results

A phase II study of ARA 290 as therapeutic strategy in no-option critical limb ischemia patients.

Approved WMOWill not start

A proof of concept study to test whether ARA 290 improves wound healing and reduces neuropathic pain in no-option patients with CLI

EPIK-P2: A Phase II double-blind study with an upfront, 16-week randomized, placebo-controlled period, to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in pediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS)

Approved WMORecruiting

This study has been transitioned to CTIS with ID 2023-508530-34-00 check the CTIS register for the current data. Primary objective:* To demonstrate the efficacy of alpelisib as measured by the proportion of participants randomized to alpelisib with…